Fig. 1
Optimized dose tucidinostat inhibits tumor growth via modulating the antitumor immune response. a Schema of the experiment. Mouse CT26 cells (5 × 105 cells) were engrafted into the flank of BALB/c mice. When established tumors were palpable 7 days after tumor cell inoculation, mice were treated with different doses (12.5, 25, 75 mg/kg, gavage, daily, n=5) of tucidinostat or DMSO as vehicle control (DMSO, n=5). b Tumor weight on day 10 post-treatment initiation. c Waterfall plot of individual tumor volume changes on day 10 post-treatment initiation. The individual tumor volume change means the ratio of the tumor volume on day 10 to that on day 0 after tucidinostat treatment. d The percentage of body weight change on day 10 post-treatment initiation. e Hematological parameters on day 10 post-treatment initiation. The blood samples were collected and determined using a routine blood test. Routine blood tests include WBC count, RBC count, PLT count, and lymphocyte count. f Flow cytometric quantification of lymphocytes (CD45+), total T cells (CD45+CD3+), CD4+ T cells (CD45+CD3+CD4+), and CD8+ T cells (CD45+CD3+CD8+) in tumor parenchyma and tumor drainage lymph nodes from CT26 tumor-bearing mice on day 10 post-treatment initiation. g Representative immunofluorescent staining for tumor-infiltrating T cells on day 10 post-treatment initiation. Red, CD3 staining; pink, CD4 staining; green, CD8 staining; blue, DAPI staining. The error bars indicate mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA. ns not significant, WBC white blood cell, RBC red blood cell, PLT platelet, CON control group, Tuc tucidinostat